72 related articles for article (PubMed ID: 20002082)
1. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.
Lim KS; Cho JY; Kim BH; Kim JR; Kim HS; Kim DK; Kim SH; Yim HJ; Lee SH; Shin SG; Jang IJ; Yu KS
Br J Clin Pharmacol; 2009 Dec; 68(6):883-90. PubMed ID: 20002082
[TBL] [Abstract][Full Text] [Related]
2. A model-informed approach to accelerate the clinical development of cofrogliptin (HSK7653), a novel ultralong-acting dipeptidyl peptidase-4 inhibitor.
Cui C; Cao F; Kong II; Wu Q; Li F; Li H; Liu D
Diabetes Obes Metab; 2024 Feb; 26(2):592-601. PubMed ID: 37953687
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, Pharmacodynamics, and Safety of Single Dose HSK7653 Tablets in Chinese Subjects with Normal or Impaired Renal Function.
Shi D; Chen L; Li G; Wu N; Zhang F; Wang X; Mu N; Chen X; Yang X; Lu J; Lu Y; Wang M; Zhang D
Clin Pharmacokinet; 2024 Feb; 63(2):227-239. PubMed ID: 38184489
[TBL] [Abstract][Full Text] [Related]
4. Biotransformation and disposition characteristics of HSK7653, a novel long-acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Bian YC; Meng J; Hu T; Ma S; Huang CR; Zhang FY; Wu QH; Zhang H; Chen XY; Miao LY
Diabetes Obes Metab; 2024 Jul; 26(7):2860-2868. PubMed ID: 38646838
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic principles and target concentration intervention.
Holford N
Transl Clin Pharmacol; 2018 Dec; 26(4):150-154. PubMed ID: 32055568
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
[TBL] [Abstract][Full Text] [Related]
7. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.
Yang SJ; Min KW; Gupta SK; Park JY; Shivane VK; Pitale SU; Agarwal PK; Sosale A; Gandhi P; Dharmalingam M; Mohan V; Mahesh U; Kim DM; Kim YS; Kim JA; Kim PK; Baik SH
Diabetes Obes Metab; 2013 May; 15(5):410-6. PubMed ID: 23170990
[TBL] [Abstract][Full Text] [Related]
8. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry.
Kim SH; Lee SH; Yim HJ
Arch Pharm Res; 2013 Oct; 36(10):1185-8. PubMed ID: 23771499
[TBL] [Abstract][Full Text] [Related]
9. Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444).
Shon JH; Kim N; Park SJ; Oh MK; Kim EY; Lee SH; Kim YH; Shin JG
Diabetes Obes Metab; 2014 Oct; 16(10):1028-31. PubMed ID: 24641348
[TBL] [Abstract][Full Text] [Related]
10. Gemigliptin, a dipeptidyl peptidase-4 inhibitor, inhibits retinal pericyte injury in db/db mice and retinal neovascularization in mice with ischemic retinopathy.
Jung E; Kim J; Kim CS; Kim SH; Cho MH
Biochim Biophys Acta; 2015 Dec; 1852(12):2618-29. PubMed ID: 26391252
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
Rhee EJ; Lee WY; Yoon KH; Yoo SJ; Lee IK; Baik SH; Kim YK; Lee MK; Park KS; Park JY; Cha BS; Lee HW; Min KW; Bae HY; Kim MJ; Kim JA; Kim DK; Kim SW
Diabetes Obes Metab; 2010 Dec; 12(12):1113-9. PubMed ID: 20977584
[TBL] [Abstract][Full Text] [Related]
12. Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo.
Jung E; Kim J; Kim SH; Kim S; Cho MH
Eur J Pharmacol; 2014 Dec; 744():98-102. PubMed ID: 25448307
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.
Choi HY; Lim HS; Kim YH; Jeon HS; Kim MJ; Lee SH; Jung JH; Lee YK; Kim HJ; Bae KS
Curr Med Res Opin; 2015 Feb; 31(2):229-41. PubMed ID: 25350224
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.
Choi HY; Kim YH; Kim MJ; Lee SH; Bang K; Han S; Lim HS; Bae KS
Drugs R D; 2014 Sep; 14(3):165-76. PubMed ID: 24962635
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.
Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):999-1024. PubMed ID: 26173919
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Filippatos TD; Athyros VG; Elisaf MS
Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):787-812. PubMed ID: 24746233
[TBL] [Abstract][Full Text] [Related]
17. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.
Deacon CF; Lebovitz HE
Diabetes Obes Metab; 2016 Apr; 18(4):333-47. PubMed ID: 26597596
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
Shin D; Cho YM; Lee S; Lim KS; Kim JA; Ahn JY; Cho JY; Lee H; Jang IJ; Yu KS
Clin Drug Investig; 2014 Jun; 34(6):383-93. PubMed ID: 24627290
[TBL] [Abstract][Full Text] [Related]
19. Absorption, metabolism and excretion of [14C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
Kim N; Patrick L; Mair S; Stevens L; Ford G; Birks V; Lee SH
Xenobiotica; 2014 Jun; 44(6):522-30. PubMed ID: 24304170
[TBL] [Abstract][Full Text] [Related]
20. The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.
Moon JY; Woo JS; Seo JW; Lee A; Kim DJ; Kim YG; Kim SY; Lee KH; Lim SJ; Cheng XW; Lee SH; Kim W
PLoS One; 2016; 11(3):e0150745. PubMed ID: 26959365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
